Cargando…
Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?
The high molecular heterogeneity of bladder tumours is responsible for significant variations in disease course, as well as elevated recurrence and progression rates, thereby hampering the introduction of more effective targeted therapeutics. The implementation of precision oncology settings support...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Impact Journals LLC
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5710962/ https://www.ncbi.nlm.nih.gov/pubmed/29207682 http://dx.doi.org/10.18632/oncotarget.19433 |